Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 106Ovarian Neoplasms 81Breast Neoplasms 81Fallopian Tube Neoplasms 51Small Cell Lung Carcinoma 42Neoplasms 41Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 25Adenocarcinoma of Lung 25Parkinson Disease 4, Autosomal Dominant Lewy Body 24Carcinoma 23Neoplasm Metastasis 20Carcinoma, Ovarian Epithelial 18Melanoma 14Lymphoma, Large B-Cell, Diffuse 14Carcinoma, Squamous Cell 14Brain Neoplasms 14Prostatic Neoplasms 13Recurrence 12Lymphoma 12Endometrial Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Esophageal Neoplasms 11Lymphoma, Non-Hodgkin 10Hodgkin Disease 10Brenner Tumor 10Urinary Bladder Neoplasms 9Central Nervous System Neoplasms 9

Interventions

Radiotherapy 2Pyridoxine 2Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Triptorelin Pamoate 1Rituximab 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Carboplatin × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡